Vipergen’s high-fidelity DEL screening technologies allow for the identification of novel hit compounds by screening over 500 million drug-like molecules in a single tube or within living cells. SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership to offer enhanced hit and lead identification services, leveraging their complementary technology platforms. By combining Vipergen’s unique DNA-encoded library (DEL) screening technologies with SARomics’ structural biology capabilities, the companies will enhance their drug discovery services by offering expedited hit identification and lead generation. We can quickly generate detailed structural information by leveraging SARomics Biostructures’ structural biology capabilities, including mapping of binding sites and binding poses for the identified compounds. This combined information will significantly enhance and accelerate the subsequent lead generation of the identified hit molecules.
